Quantumzyme Corp., a biotransformation company developing sustainable enzyme-based solutions, has announced continued progress on strategic corporate initiatives including a planned four-for-one forward stock split and advancement of its corporate name and trading symbol change. These moves are designed to better position the company for its next phase of development as it focuses on advancing enzyme innovation through artificial intelligence and computational modeling.
The company confirmed its Board of Directors has authorized a 4-for-1 forward stock split of its issued and outstanding common stock. According to company statements, the forward split is intended to enhance the company's public market profile by recalibrating its capital structure to facilitate greater flexibility in the company's outstanding share structure, support administrative efficiency in the trading of its common stock, and align the company's public share profile with its current stage of development. The forward split will be submitted for processing only after completion of the company's pending corporate name and trading symbol change.
Quantumzyme Corp. is now in the final stages of completing a corporate name change to Quantum Genesis AI Corp., a change that reflects the company's strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates that the name and corresponding trading symbol change will be completed in the near term. Immediately following effectiveness of the new name and symbol, the company intends to submit the forward stock split to the Financial Industry Regulatory Authority (FINRA) in accordance with applicable regulatory requirements.
Naveen Kulkarni, President of Quantumzyme Corp., stated that the planned corporate rebranding and capital structure initiatives are intended to better align the company's public market profile with its long-term strategic direction. "Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap," Kulkarni explained.
If and when approved, the forward stock split will increase the number of outstanding shares of common stock while proportionally adjusting the per-share trading price. The company believes this action may provide several potential benefits going forward, including increased flexibility to support future corporate initiatives. The company emphasizes that the forward split is not intended to, and will not by itself, change the company's overall market capitalization. The forward stock split will not affect the proportional ownership interests of existing shareholders, except for minor adjustments that may result from the treatment of fractional shares in accordance with customary transfer agent procedures.
The company expects to provide additional updates regarding the effectiveness of the corporate name and symbol change, as well as the timing and status of the forward stock split submission and review process, through subsequent public disclosures. The planned forward stock split remains subject to regulatory review and approval, and there can be no assurance regarding the timing or completion of the split. For more information and updates, please visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
